title: Meeting notes from ICAAC. NRTI-only regimens: making a comeback?
authors.forename: Paul E
authors.initials: PE
authors.lastname: Sax
mesh_terms: D015224:Dideoxynucleosides / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D012367:RNA, Viral / Q000097:blood; D016032:Randomized Controlled Trials as Topic; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D019562:Viral Load; D015215:Zidovudine / Q000008:administration & dosage*; D000099227:Abacavir
chemical_list: D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; C418262:abacavir, lamivudine, and zidovudine drug combination; D000099227:Abacavir; C109078:lamivudine, zidovudine drug combination